A flare of pre‐existing erythema multiforme following BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccine

Lavery, Michael Joseph; Nawimana, Shainy; Parslew, Richard; Stewart, Laura S

doi:10.1111/ced.14714

Cited by 36 publications

(39 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6 ). 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 ...…”

Section: Discussionunclassified

“…Indeed, there are previous reports of EM occurring after the application of other vaccines. 28 , 36 , 45 Similar to several cases of COVID‐19 infection, anti‐SARS‐CoV‐2 vaccines may also trigger itchy maculopapular, morbilliform rashes resembling common drug eruption or infection‐associated exanthemas. 35 , 36 Most rashes were observed a few days after vaccination and cleared within a week.…”

Section: Type I and Type Iv Hypersensitivity Reactionsmentioning

confidence: 99%

“…chilblain‐like lesions, morbilliform rashes and vasculitis) SARS‐CoV‐2 vaccines appear to have also the potential to induce a broad spectrum of cutaneous adverse events. 1 , 2 , 3 , 4 , 5 In this review article, 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Cutaneous findings following COVID‐19 vaccination: review of world literature and own experience

Gambichler

Boms²,

Susok

et al. 2021

Acad Dermatol Venereol

169

237

View full text Add to dashboard Cite

There is growing evidence that not only the novel coronavirus disease (COVID‐19) but also the COVID‐19 vaccines can cause a variety of skin reactions. In this review article, we provide a brief overview on cutaneous findings that have been observed since the emerging mass COVID‐19 vaccination campaigns all over the world. Unspecific injection‐site reactions very early occurring after the vaccination are most frequent. Type I hypersensitivity reactions (e.g. urticaria, angio‐oedema and anaphylaxis) likely due to allergy to ingredients may rarely occur but can be severe. Type IV hypersensitivity reactions may be observed, including delayed large local skin lesions (“COVID arm”), inflammatory reactions in dermal filler or previous radiation sites or even old BCG scars, and more commonly morbilliform and erythema multiforme‐like rashes. Autoimmune‐mediated skin findings after COVID‐19 vaccination include leucocytoclastic vasculitis, lupus erythematosus and immune thrombocytopenia. Functional angiopathies (chilblain‐like lesions, erythromelalgia) may also be observed. Pityriasis rosea‐like rashes and reactivation of herpes zoster have also been reported after COVID‐19 vaccination. In conclusion, there are numerous cutaneous reaction patterns that may occur following COVID‐19 vaccination, whereby many of these skin findings are of immunological/autoimmunological nature. Importantly, molecular mimicry exists between SARS‐CoV‐2 (e.g. the spike‐protein sequences used to design the vaccines) and human components and may thus explain some COVID‐19 pathologies as well as adverse skin reactions to COVID‐19 vaccinations.

show abstract

Section: Discussionunclassified

Section: Type I and Type Iv Hypersensitivity Reactionsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cutaneous findings following COVID‐19 vaccination: review of world literature and own experience

Gambichler

Boms²,

Susok

et al. 2021

Acad Dermatol Venereol

169

237

View full text Add to dashboard Cite

show abstract

“…However, about 20% of 117 patients had a worsening of their DAPSA score [24]. Other conditions potentially worsened by the COVID-19 vaccination are atopic dermatitis [6,20,42], lichen ruber planus [6], chronic spontaneous urticaria [64], bullous pemphigoid [65], pemphigus vulgaris [65], pityriasis rubra pilaris [66], urticarial vasculitis, cutaneous small-vessel vasculitis [67], erythema multiforme [68], and Darier's disease [69]. Finally, one case of transition from subacute cutaneous lupus erythematosus into systemic lupus erythematosus was also described [70].…”

Section: Flare Of Existing Dermatosesmentioning

confidence: 99%

Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines

Bellinato

Maurelli

Gisondi

et al. 2021

JCM

View full text Add to dashboard Cite

Many patients are receiving SARS-CoV-2 vaccinations, which have been associated with a variety of adverse effects. Cutaneous adverse reactions to SARS-CoV-2 vaccinations have been progressively reported, but they have not been reviewed according to their morphological clinical patterns. The objective of this review was to summarize the existing data concerning the cutaneous adverse reactions following SARS-CoV-2 vaccines and group them according to common morphological and pathogenetic patterns. We reviewed the English language literature up to 15 August 2021, using predefined keywords to identify the relevant studies evaluating cutaneous adverse reactions associated with SARS-CoV-2 vaccines. We search for recurrent morphological patterns sharing clinical signs and symptoms and physio-pathological mechanisms. Timing to onset following the first or booster dose of the vaccine, predisposing conditions, therapeutic management, and outcome were also collected. Among the dermatological manifestations associated with SARS-CoV-2 vaccinations, we distinguished: (1) new onset reactions and (2) flares of preexisting dermatoses. The most common were injection site reactions, affecting 30–70% and generally mild or moderate. Small case series or single case reports included filler reactions, exanthemas, vascular lesions, urticaria, eczematous dermatitis, autoimmune bullous reactions, and severe cutaneous adverse reactions. In addition, the exacerbation of chronic immuno-mediated dermatoses (mainly psoriasis and atopic dermatitis) and reactivations of herpes infection were reported. The cutaneous reactions were generally mild, self-limiting, and resembled common cutaneous drug eruptions and/or COVID-19 skin manifestations.

show abstract

“…Nevertheless, there have been few reports of flares in patients with rheumatic diseases following vaccination for other diseases such as influenza and hepatitis B [3,4]. Regarding COVID-19, disease flares following vaccination have been reported in the context of preexisting rheumatoid arthritis, IgA nephropathy, leukocytoclastic vasculitis, erythema nodosum, and psoriasis [5][6][7][8][9].…”

Section: Introductionmentioning

confidence: 99%

A flare of Still’s disease following COVID-19 vaccination in a 34-year-old patient

et al. 2021

View full text Add to dashboard Cite

A flare of pre‐existing erythema multiforme following BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccine

Cited by 36 publications

References 7 publications

Cutaneous findings following COVID‐19 vaccination: review of world literature and own experience

Cutaneous findings following COVID‐19 vaccination: review of world literature and own experience

Cutaneous Adverse Reactions Associated with SARS-CoV-2 Vaccines

A flare of Still’s disease following COVID-19 vaccination in a 34-year-old patient

Contact Info

Product

Resources

About